Status | Study |
Recruiting |
Study Name: Efficacy and Safety of Three Different Aflibercept Regimens in Subjects With Diabetic Macular Edema (DME) Condition: Macular Edema Date: 2016-06-28 Interventions: Biological: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321) |
Recruiting |
Study Name: A Study to Assess the Effectiveness of Aflibercept in Routine Clinical Practice in Patients With Diabetic Macular Oedema Condition: Macular Edema Date: 2016-05-19 Interventions: Drug: Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321) |
Terminated |
Study Name: Open-label, Multli-center, Phase 1b/2a Clinical Trial Designed to Evaluate the Safety and Efficacy of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution in Patients With Macular Edema Condition: Macular Edema Date: 2015-06-26 Interventions: Drug: Dexamethasone Phosphate Ophthalmic Transscleral iontophoresis delivery of EGP-437 (dexamethasone p |
Recruiting |
Study Name: Acute Pseudophakic Cystoid Macular Edema Treatment Trial: Intravitreal Ranibizumab Versus Triamcinolone Acetonide Condition: CYSTOID MACULAR EDEMA Date: 2014-11-04 Interventions: Drug: Ranibizumab, Intravitrea |
Withdrawn |
Study Name: Frequent Dosing Regimen of Lucentis for Subjects With Persistent Diabetic Macular Edema Despite Standard antiVEGF Dosing Condition: Persistent Diabetic Macular Edema Date: 2014-04-29 Interventions: Drug: ranibizumab ranibizumab |
Completed |
Study Name: A Phase 1, Open-Label Study of Teprotumumab in Patients With Diabetic Macular Edema (DME) Condition: Diabetic Macular Edema Date: 2014-03-27 Interventions: Drug: Teprotumumab Teprotumumab 20mg/kg administered by intravenous infusion every 3 weeks for 3 infusio |
Completed |
Study Name: Relating Retinal Structural and Functional Parameters to Visual Acuity in Eyes Undergoing Treatment for Diabetic Macular Edema Condition: Diabetic Macular Edema Date: 2014-03-07 |
Active, not recruiting |
Study Name: Safety and Efficacy of Ranibizumab for Diabetic Macular Edema Condition: Diabetic Macular Edema Date: 2013-10-29 Interventions: Drug: Ranibizumab Monthly inje |
Completed |
Study Name: Comparative Effectiveness Study of Intravitreal Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema Condition: Diabetic Macular Edema Date: 2012-06-21 Interventions: Drug: 2.0 mg intravitreal aflibercept |
Completed |
Study Name: Japanese Safety Study of VEGF Trap-Eye in DME (Diabetic Macular Edema) Condition: Macular Edema Date: 2012-01-16 Interventions: Biological: VEGF Trap-Eye (BAY86-5321) Subjects in the VEGF Trap-Eye group will receive intravitreal inj |